Tag: Seattle Genetics
Seattle Genetics Changes Corporate Name to Seagen
Seattle Genetics confirmed that it has changed it's corporate name to Seagen. According to a statement issued by the company, the new name reflects...
Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in...
A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival (OS) compared to chemotherapy.
Globally, approximately...
Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as...
Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle Genetics/Astellas Pharma) in combination with...
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics
One day after Bristol-Myers Squibb and Five Prime Therapeutics announced that a randomized Phase II study testing the combination of cabiralizumab and nivolumab (Opdivo®),...
European Regulators Approve Polatuzumab Vedotin, Triggering Milestone Payment for Seattle Genetics
The European Commission's conditional marketing authorization of polatuzumab vedotin (Polivy®; Genentech/Roche) earlier this week triggered a milestone payment which Seattle Genetics will receive from...
Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial...
The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)* for the treatment of adult...
ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...
Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application...
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin, also known as ASG-22CE,...
5 Things You Need To Know This Week About ADCs –...
This is the second article in my series of updates about the goings on in the world of ADCs over the last two weeks....
Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...
Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...
